Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2

Cancer Biomarkers

Volumn 12, Issue 4-5, 2012, Pages 155-167

  Zhang, Chunlin ^a   Zhao, Yao ^a   Zeng, Bingfang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Bcl 2; chemoresistance; Cyclin D1; Osteosarcoma; RNA interference

Indexed keywords

CYCLIN D1; DOXORUBICIN; LENTIVIRUS VECTOR; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL ASSAY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LONG TERM EXPOSURE; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HUMANS; INHIBITORY CONCENTRATION 50; LENTIVIRUS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 84876270484     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130305     Document Type: Article

References (44)

1. Poletajew S, Fus L, Wasiutýnski A. Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors. Ortop Traumatol Rehabil. 2011; 13(6): 537-45.
2. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4): 633-638. (Pubitemid 351264359)
3. J Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N. Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group. Cancer. 2012; 118(18): 4597-605.
4. O'Driscoll L. Mechanisms of drug sensitivity and resistance in cancer. Curr Cancer Drug Targets. 2009; 9(3): 250-251.
5. Katiyar SK, Roy AM, Baliga MS. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation, Mol Cancer Ther. 2005; 4(2): 207-216. (Pubitemid 40340200)
6. Ye Z, Peng H, Fang Y, Feng J, Yang DS. The construction of the eukaryotic expression plasmid pcDNA3.1/azurin and the increased apoptosis of U2OS cells transfected with it. Cell Mol Biol Lett. 2007; 12(3): 407-421.
7. Pösl M, Amling M, Werner M, Bäsler I, Salzer-Kuntschik M, Winkler K, Delling G. Osteosarcoma-apoptosis and proliferation. Study of bcl-2 expression. Pathologe. 1994; 15(6): 337-344.
8. Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, Trieb K, Kotz R, Toma CD. Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol. 2008; 134(2):237-244. (Pubitemid 350234069)
9. Eliseev RA, Dong YF, Sampson E, Zuscik MJ, Schwarz EM, O'Keefe RJ, Rosier RN, Drissi MH. Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene. 2008; 27(25): 3605-3614. (Pubitemid 351793799)
10. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M. Inhibition of Cyclin D1 Expression in Human Pancreatic Cancer Cells Is Associated with Increased Chemosensitivity and Decreased Expression of Multiple Chemoresistance Genes. Cancer Res. 1999; 59(14): 3505-3511. (Pubitemid 29334515)
11. Bai J, Nakamura H, Ueda S, Kwon YW, Tanaka T, Ban S, Yodoi J. Proteasome-dependent degradation of Cyclin D1 in 1-methyl-4-phenylpyridinium ion (MPP+)-induced cell cycle arrest. J Biol Chem. 2004; 279(37): 38710-38714. (Pubitemid 39296028)
12. Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer. 2012; 118(3): 750-760.
13. Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, Du X, Han W. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012; 33(1): 220-225
14. El-Kady A, Sun Y, Li YX, Liao DJ. Cyclin D1 inhibits whereas c-Myc enhances the cytotoxicity of cisplatin in mouse pancreatic cancer cells via regulation of several members of the NF-κB and Bcl-2 families. J Carcinog. 2011; 10: 24.
15. Queenie Lai Kwan Lama, Shengjun Wangb, Otis King Hung Ko, PaulW. Kincade, Liwei Lu. Leptin signaling maintains Bcell homeostasis via induction of Bcl-2 and Cyclin D1. 2010; 107(31): 13812-13817.
16. Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y, Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol Rep. 2000; 7(4): 859-866.
17. Chalk AM, Warfinge RE, Georgii-Hemming P, Sonnhammer EL. siRNAdb: A database of siRNA sequences. Nucleic Acids Res. 2005; 33: D131-D134. (Pubitemid 40207845)
18. Thakur N, Qureshi A, Kumar M. VIRsiRNAdb: A curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Research. 2012; 40 (D1): D230-D236.
19. Saxena S, Singh N, Ranade SA, Babu SG. Strategy for a generic resistance to geminiviruses infecting tomato and papaya through in silico siRNA search. Virus Genes. 2011; 43(3): 409-34.
20. Park YK, Park SM, Choi YC, Lee D, Won M, Kim YJ. AsiDesigner: Exon-based siRNA design server considering alternative splicing. Nucleic Acids Res. 2008; 36(Web Server issue): W97-103.
21. Kim YJ. Computational siRNA design considering alternative splicing. Methods Mol Biol. 2010; 623: 81-92
22. Caffrey DR, Zhao J, Song Z, Schaffer ME, Haney SA, Subramanian RR, Seymour AB, Hughes JD. si RNA off-target effects can be reduced at concentrations that match their individual potency. PLoS ONE. 2011; 6(7): e21503.
23. Persengiev SP, Zhu X, Green MR. Nonspecific. concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA. 2004; 10(1): 12-18. (Pubitemid 38018731)
24. Gu S, He J. Daphnoretin induces cell cycle arrest and apoptosis in human osteosarcoma (HOS) cells. Molecules. 2012; 17(1): 598-612.
25. Sharma V, Anderson D, Dhawan A. Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria mediated apoptosis in human liver cells (HepG2). Apoptosis. 2012; 17(8): 852-70.
26. Yao Zhao, Chun-lin Zhang, Bing-fang Zeng, Xiao-san Wua, Tian-Tian Gao, Yoshino Oda. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun. 2009; 390(3): 642-647.
27. Mimeault M, Hauke R, Baktra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther. 2008; 83(5): 673-691. (Pubitemid 351559599)
28. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood. 1996; 88(5): 1805-1812. (Pubitemid 26307078)
29. Li Y, Tanaka K, Li X, Okada T, Nakamura T, Takasaki M, Yamamoto S, Oda Y, Tsuneyoshi M, Iwamoto Y. Cyclindependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. Int J Cancer. 2007; 121(6): 1212-1218. (Pubitemid 47293787)
30. Fromigué O, Haÿ E, Modrowski D, Bouvet S, Jacquel A, Auberger P, Marie PJ. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006; C13(11): 1845-1856. (Pubitemid 44542398)
31. Kim JK, Diehl JA. Nuclear cyclinD1: An oncogenic driver in human cancer, J Cell Physiol. 2009; 220(2): 292-296.
32. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006; 25(38): 5220-5227. (Pubitemid 44299080)
33. Caldon CE, Sutherland RL, Musgrove E. Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle. 2010; 9(10): 1918-1928.
34. Broceño C, Wilkie S, Mittnacht S. RB activation defect in tumor cell lines. Proc Natl Acad Sci USA. 2002; 99(22): 14200-14205. (Pubitemid 35257649)
35. Merli M, Benassi MS, Gamberi G, Ragazzini P, Sollazzo MR, Molendini L, Magagnoli G, Ferrari C, Maltarello MC, Picci P. Expression of G1 phase regulators in MG-63 osteosarcoma cell line. Int J Oncol. 1999; 14(6): 1117-1121.
36. Zhang Y, Song L, Cai L, Wei R, Hu H, Jin W. Effects of baicalein on apoptosis, cell cycle arrest, migration and invasion of osteosarcoma cells. Food Chem Toxicol. 2013; 53: 325-33.
37. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, SasakiMS, Kotoura Y, Yamamuro T.Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994; 54(11): 3024-3028.
38. Lindström MS, Nistér M. Silencing of ribosomal protein S9 elicits a multitude of cellular responses inhibiting the growth of cancer cells subsequent to p53 activation, PLoS One. PLoS One. 2010; 5(3): e9578.
39. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA. 1990; 87(15): 5863-5867.
40. Chandar N, Billig B,McMaster J, Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells, Br J Cancer. 1992; 65(2): 208-214.
41. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003; 11(3): 577-590 (Pubitemid 36385115)
42. Jacob T, Hingorani A, Ascher E. P53 Gene Therapy Modulates Signal Transduction in the Apoptotic and Cell Cycle Pathways Downregulating Neointimal Hyperplasia. Vasc Endovascular Surg. 2012; 46(1): 45-53.
43. Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH, Liao JD. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgeneexpressing pancreatic tumor cell line. Clin Cancer Res. 2005; 11(16): 6075-6086. (Pubitemid 41170340)
44. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications. Cell Mol Life Sci. 2004; 61(17): 2189-2199. (Pubitemid 39280118)